Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGM0504 vs Tirzepatide in Adults with Obesity
NCT06911203Phase 2Completed
- Sponsor
- BrightGene Bio-Medical Technology
- Start
- Apr 2025
- Primary completion
- Jan 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BGM0504 in obesity, sponsored by BrightGene Bio-Medical Technology. Started Apr 2025; status: completed.
02
Drugs
BGM0504
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06911203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06911203.